AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03082066 — intervention group
Intervention type: OTHER
Intervention: CT or MRI scan
Description: CT or MRI performed for underlying disease. CT and MRI scans used to asses bone and soft tissue diameter
Study NCT01138254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WSTM TY101 FIR emitter (Far infrared therapy)
Description: A WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) will be used for FIR therapy. The electrified ceramic plates of this emitter generate electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 mili watt\<mw>/cm2 when the top radiator is set at a distance between 30 and 20 cm above the skin surface respectively. In this study, the top radiator will be set at a height of 25 cm above the surface of bilateral lower legs and the treatment time will be set at 40 minutes three times weekly (TIW) for ESRD patients for 6 months.
Study NCT01138254 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: no intervention
Description: no intervention
Study NCT04362046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopic uterine resection
Description: Hysteroscopic Resection will be evaluated as a fertility-sparing treatment for patients with early Endometrial Cancer or Endometrial Hyperplasia (atypical or persisting typical) who fail progestin therapy. Failure of progesterone therapy is defined as: (a) Unsuccessful eradication of hyperplasia or cancer in the uterus or (b) Intolerance to the side effects of th hormone therapy.~HR is a common gynecologic procedure that is offered to women for treatment of several benign gynecologic conditions. The conduct, risks, and complications of it are well-understood. In relation to this protocol, it is the indication for HR that constitutes the experimental intervention including the assessment of it's outcome. Patients deemed appropriate for hysteroscopic endomyometrial resection will be counselled on the nature of the procedure along with its risks and complications.
Study NCT04354389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAS181
Description: 4.5 mg b.i.d
Study NCT03058289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INT230-6
Description: INT230-6 is clear sterile solution administered by injection directly into the tumor to be treated.~The product contains a cell permeation agent with cisplatin and vinblastine sulfate at fixed concentrations.
Study NCT00789594 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: laboratory monitoring alerts
Description: laboratory monitoring alerts
Study NCT00789594 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Result management module
Description: Result management module
Study NCT02884193 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brief Cooling
Description: Brief Application of cold, for a period of up to 30 seconds on a body surface which seeks to promote the activation of the nervous system to produce increased excitability.
Study NCT04354389 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: q.d. or b.i.d.
Study NCT04354389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAS181
Description: 4.5 mg q.d.
Study NCT00986375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Description: patients will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
Study NCT00986375 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Group (ACG)
Description: Patients in the ACG will get an interactive computerized standard program
Study NCT04393389 — intervention group
Intervention type: DEVICE
Intervention: AcoArt Orchid (0.035), AcoArt Tulip (0.018) and AcoArt Litos (0.014) percutaneous transluminal angioplasty (PTA) paclitaxel drug coated balloon catheter manufactured by Acotec Scientific Co., Ltd.
Description: All comers Post Market Clinical Follow-up to continue the surveillance of the Acotec Drug Coated PTA Catheter AcoArt Orchid, AcoArt Tulip and AcoArt Litos in lower limb treatment
Study NCT00429338 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AIR-MRSI
Description: 3T Magnetic Resonance Spectroscopic Imaging (MSRI) scan performed with an air-filled endorectal coil (AIR-MRSI).
Study NCT00429338 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PFC-MRSI
Description: 3T Magnetic Resonance Spectroscopic Imaging (MSRI) scan performed with a perfluorocarbon compound (PFC)-filled endorectal coil (PFC-MRSI).
Study NCT02884193 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Cold
Description: Prolonged application of cold, for at least 5 minutes or more, on a body surface that aims to reduce nervous system activation by reducing the NCV.
Study NCT02884193 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Ice Bag
Description: Placebo application through an ice bag empty.
Study NCT04254575 — intervention group
Intervention type: OTHER
Intervention: None, observational study only (no interventions)
Description: None, observational study only (no interventions)
Study NCT00172003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study NCT04115891 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Anxiety scale
Description: Anxiety Face Image Scale (FIS) assessment in a separate room with face to face interview.
Study NCT04115891 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anxiety scale
Description: Anxiety Face Image Scale (FIS) assessment in a separate room with face to face interview.
Study NCT04115891 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Pain scale - 1
Description: Face, Legs, Activity, Cry, Consolability (FLACC), to assess objective operational pain after anesthesia injection and tooth extraction
Study NCT04115891 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain scale - 1
Description: Face, Legs, Activity, Cry, Consolability (FLACC), to assess objective operational pain after anesthesia injection and tooth extraction
Study NCT04115891 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Pain scale - 2
Description: Wong Baker Pain Rating scale (WBS), to assess subjective operational pain after anesthesia injection and tooth extraction
Study NCT04115891 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain scale - 2
Description: Wong Baker Pain Rating scale (WBS), to assess subjective operational pain after anesthesia injection and tooth extraction
Study NCT04115891 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inhalation
Description: lavender oil inhalation in a separate room for 3 minutes prior to interventions
Study NCT01320527 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutriceutical formulation
Description: Two pills that collectively contain: folic acid (400µg), Vitamin B12 (6µg), Vitamin E (as alpha-tocopherol; 30 IU), S-adenosylmethionine (SAM; 400mg), N-acetyl cysteine (NAC; 600mg) and Acetyl-L-carnitine (ALCAR; 500mg). Taken once daily for duration of study (1 year).
Study NCT01320527 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A mixture of 6 vitamins and nutriceuticals
Study NCT01345825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Week 1: 2 sets x 12 repetitions at 12 RM Week 2: 3 sets of 12 repetitions with 12 RM Week 3: 3 sets of 10 repetitions with 10 RM Week 4-5: 3 sets of 10 repetitions with 10 RM Week 6: 3 sets of 8 repetitions with 8 RM Week 7: 4 sets of 8 repetitions with 8 RM Week 8: 4 sets of 8 repetitions with 8 RM
Study NCT02407236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: Placebo will be administered as intravenous infusion.
Study NCT02407236 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo IV
Description: Placebo will be administered as intravenous infusion.
Study NCT02407236 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo SC
Description: Placebo will be administered Subcutaneously.
Study NCT00370942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW823093C A
Description: A=45 mg
Study NCT00370942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW823093C B
Description: B=30 mg
Study NCT02407236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC
Description: Placebo will be administered Subcutaneously.
Study NCT02407236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab IV
Description: Ustekinumab will be administered as intravenous infusion at Week 0 or Week 8 in Induction Study.
Study NCT02407236 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ustekinumab IV
Description: Ustekinumab will be administered as intravenous infusion at Week 0 or Week 8 in Induction Study.
Study NCT00370942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW823093C C
Description: C=25 mg
Study NCT02628106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipo-PGE1
Description: all patients received 10 ug lipo-PGE1 intravenously once daily for consecutive 14 days
Study NCT02407236 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ustekinumab SC
Description: Ustekinumab will be administered as subcutaneously.
Study NCT02407236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab SC
Description: Ustekinumab will be administered as subcutaneously.
Study NCT00284258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPT-11 and TS-1
Description: TS-1 was administered orally at 40-60 mg twice daily for 14 days with a rest period of 14 days as one course. CPT-11 was administered intravenously 125 mg per square meter at day1 and day14 in 4 weeks as one course.
Study NCT00284258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CPT-11, 5-FU and l-LV
Description: Patients were administered FOLFIRI every 2 weeks in one course. FOLFIRI:CPT-11 150 mg per square meter on day1 with l-LV 200 mg per square meter administered as a 2-hour infusion before 5-FU 400 mg per square meter administered as an intravenous bolus injection, and 5-FU 2400 mg per square meter as a 46-hour infusion immediately after 5-FU bolus injection on day1 in 2 weeks.
Study NCT01762592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodine (124I) Girentuximab
Description: i.v.
Study NCT03330093 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Health in Preschoolers
Description: In-person, family-based behavioral intervention
Study NCT03330093 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health and Safety Intervention
Description: In-person, family-based behavioral intervention
Study NCT03497390 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EMERALD intervention
Description: EMERALD consists of a 1-year multi-component structured program led by nurses and held 4-weekly for the first 3 months, followed by maintenance program, peers support and telephone calls.
Study NCT03497390 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Usual care without any workshop or program
Study NCT03081819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH003
Description: Herbal medicine for cancer treatment
Study NCT02080585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity advice.
Description: Subjects receive advice regarding physical activities.
Study NCT00649805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil Hydrochloride Extended-Release Capsules, 300 mg
Description: 300mg, single dose applesauce
Study NCT00649805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verelan® PM Extended-Release Capsules, 300 mg
Description: 300mg, single dose applesauce
Study NCT04379375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge
Description: Application of behavior-change strategies based on principles of behavioral economics, decision-making heuristics, psychological/environmental variables.
Study NCT04379375 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nudge
Description: Application of behavior-change strategies based on principles of behavioral economics, decision-making heuristics, psychological/environmental variables.
Study NCT05759260 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Observation
Study NCT04773431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSCD101 (Cultured Autologous Limbal Epithelial Cell Sheet) transplantation
Description: LSCD101 (Cultured Autologous Limbal Epithelial Cell Sheet) is transplanted in the lesion.
Study NCT01183598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: maintenance dose
Study NCT03956992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mouth gel
Description: Stop using the mouth gel
Study NCT00785590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermacyd PH_DETINLYN (Lactic Acid)
Study NCT04789629 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low level laser therapy
Description: 3 session per week laser with exercises
Study NCT03533816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EAGD T-cell infusion (Phase I)
Description: The Alpha Beta (α/β) T-Cell Depletion System utilizes the CliniMACS instrument to yield a gamma delta (γδ) enriched cell therapy product.
Study NCT03533816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EAGD T-cell infusion (Expansion)
Description: The Alpha Beta (α/β) T-Cell Depletion System utilizes the CliniMACS instrument to yield a gamma delta (γδ) enriched cell therapy product.
Study NCT03462927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MC2-01 Cream
Description: MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%)
Study NCT03462927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAL/BDP combination
Description: Calcipotriene/betamethasone (calcipotriene/ betamethasone dipropionate, w/w 0.005%/0.064%)
Study NCT00249808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efalizumab - anti-CD11a recombinant human monoclonal antibody
Description: Participants will receive efalizumab 1.0 milligram per kilogram (mg/kg) (with an initial conditioning dose of 0.7 mg/kg) once weekly by subcutaneous injection for 12 weeks (first treatment \[FT\]). Depending on the response at Week 12, participants could receive additional 8 to 12 weekly injections of efalizumab 1.0 mg/kg.
Study NCT01762384 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LSC
Description: subjects of this group are submitted to surgical treatment of laparoscopic sacral colpopexy.
Study NCT01762384 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified PFRS
Description: subjects of this group are submitted to modified pelvic floor reconstructive surgery with mesh.
Study NCT01762384 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gynemesh
Description: Both surgeries will be conducted using mesh constructed from polypropylene mesh.
Study NCT01297894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: colistin
Description: Colistimethate sodium 2.5-5mg/kg of colistin base
Study NCT01297894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: colistin plus fosfomycin
Description: colitimethate sodium 2.5-5mg/kg iv plus fosfomycin 2gm iv every 12 hours
Study NCT04044781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPN14770, T2310
Description: Subjects will be administered radio ligand T2310 and BPN14770 to determine brain occupancy of BPN14770.
Study NCT00989196 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human-cl rhFVIII
Description: 50 IU/kg for PK dose
Study NCT00989196 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Kogenate FS
Description: 50 IU/kg for PK dose
Study NCT00482742 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CiTop(TM) Guidewire
Study NCT03058289 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-PD-1 antibody
Description: The anti-PD-1 antibody will be added concomitantly with INT230-6 as noted in cohort DEC and DEC2
Study NCT03058289 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CTLA-4 antibody
Description: The anti-CTLA-4 antibody will be added concomitantly with INT230-6 as noted in cohort FEC
Study NCT02278055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223
Study NCT01565057 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sedimenting meal
Description: The active system quickly forms a sedimenting layer of small particles that contain most of the caloric content of the system. This system is made by adding finely grated cheese (particle size 0.5-2 mm) to yoghurt and consumption is followed by drinking 327 ml water.
Study NCT00443872 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: orally disintegrating selegiline (Zelapar)
Description: 1.25 mg once daily orally disintegrating selegiline for 6 weeks with an increase to 2.5 mg once daily orally disintegrating selegiline for remaining 6 weeks if tolerated
Study NCT04182477 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Montreal Cognitive Assessment
Description: Neuro-cognitive test evaluating general mental status and performance
Study NCT03861104 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: medical educational video
Description: information based on visual and auditory communication
Study NCT03302026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Realtime biofeedback using fMRI
Description: Real-time fMRI (rt-fMRI) allows for rapid analysis of brain activation while an individual is actively performing a task, and can be used to provide real-time neurofeedback to individuals during fMRI scanning. Using neurofeedback, individuals can learn to modulate activity in specific regions of the brain. We propose to use rt-fMRI neurofeedback training to help smokers consciously modulate activation in areas related to cravings and self-control in order to improve control smoking urges. Participants will complete four sessions: an intake session and 3 scanning visits. The primary outcome is the ability to resist smoking during a validated smoking lapse paradigm.
Study NCT01696058 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tiotropium
Description: marketed product
Study NCT01696058 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo matching Olodaterol
Description: one dose
Study NCT01696058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: marketed product
Study NCT01696058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol
Description: one dose
Study NCT03510962 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: no intervention
Description: Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test mixed fruit juice without any intervention.
Study NCT03510962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 2: tap water gargle
Description: The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
Study NCT03510962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 3: 0.2% Chlorhexidine
Description: The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
Study NCT03510962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 4: Fluoridated tooth paste
Description: The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes using tooth paste as an intervention.
Study NCT03510962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 5: Polyol containing gum
Description: The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes chewing as an intervention.
Study NCT03510962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 6: 1% sodium bicarbonate solution
Description: The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
Study NCT04624919 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hot/Dry
Description: Work is completed in a hot/dry environment.
Study NCT04624919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm/Humid
Description: Work is completed in a warm/humid environment